MicroRNA 215 (miR-215)

MicroRNA 215 (miR-215) is a highly conserved, short non-coding RNA molecule (about 22 nucleotides) processed from a 70-nucleotide precursor; it regulates gene expression by binding to complementary sequences on target mRNAs, resulting in translational inhibition or mRNA degradation[4][5][2]. It plays vital roles in cell cycle control, cell proliferation, apoptosis, tissue development, migration, and metabolic regulation[1][2][4]. miR-215 primarily acts as a tumor suppressor in various cancers—including colorectal, gastric, renal, lung, and pancreatic cancers—by targeting genes such as epiregulin (EGFR ligand), HOXB9, thymidylate synthase, and factors involved in cell adhesion and apoptosis[1][2]. Aberrant expression of miR-215 is associated with cancer progression, drug resistance (notably to 5-fluorouracil), and other diseases including major depressive disorder[3]. Its stable expression and mechanistic involvement in pathogenic processes make it a promising biomarker and potential therapeutic target for DNA/RNA-based drugs in oncology and other fields[2][4][5].

Other names

MIR215hsa-mir-215MIRN215miRNA215mir-215

RNA interference: miR-215 binds mRNA targets such as epiregulin (EREG), HOXB9, thymidylate synthase, and others, inhibiting protein translation or destabilizing mRNA. Tumor suppression: blocks proliferative and migratory pathways in cancer via direct mRNA targeting